Health Care Resource Utilization and Costs Associated with Disease Progression in Ovarian Cancer
Authors:
Open Access
- 1 April 2022
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (6) , 2544-2561
Abstract
Introduction Ovarian cancer (OC) is one of the leading causes of cancer mortality among women in the United States. With the approval of first-line maintenance therapies, patients with OC experienced prolonged first-line progression-free survival. While the literature addresses some costs associated with OC, further research is needed on the costs of progression that are potentially deferred or prevented by early maintenance. The objective of this study was to capture the health care resource utilization and costs of patients with advanced OC who never received poly(ADP ribose) polymerase (PARP) inhibitor maintenance. Methods We conducted a descriptive retrospective analysis of treatment patterns and the consequences of progression through several lines of therapy (LOTs) in patients with OC, using claims from commercial and Medicare Advantage health plan members in the United States from the Optum Research Database between January 1, 2010, and April 30, 2019. Patients were required to have an index OC diagnosis (≥ 2 non-diagnostic claims). We examined up to 4 LOTs and the time between treatments. Results A total of 5498 women met the eligibility criteria. As the number of LOTs increased, the median duration of each line decreased from 137 days in LOT1 to 94 days in LOT4, and the time between lines also decreased from 245 to 0 days. Ambulatory care visits were a major driver of health care resource utilization, with a median of about 6 monthly visits during active treatment. The mean total monthly health care costs for patients with at least 2 LOTs were US$8588 (SD: $8533) before LOT2 and increased to $15,358 (SD: $21,460) during or after LOT2. Conclusions Prolonging progression-free survival after first-line treatment in patients with OC may provide the opportunity to delay or prevent later treatment, the financial toxicity felt by patients, and the economic burden to the health care system associated with progression.Keywords
Funding Information
- AstraZeneca
This publication has 18 references indexed in Scilit:
- Diagnosis and Management of Ovarian Cancer.2016
- The Cost of Initial Care for Medicare Patients With Advanced Ovarian CancerJournal of the National Comprehensive Cancer Network, 2016
- Financial Insolvency as a Risk Factor for Early Mortality Among Patients With CancerJournal of Clinical Oncology, 2016
- Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapyTherapeutic Advances in Medical Oncology, 2014
- “Platinum resistant” ovarian cancer: What is it, who to treat and how to measure benefit?Gynecologic Oncology, 2014
- Washington State Cancer Patients Found To Be At Greater Risk For Bankruptcy Than People Without A Cancer DiagnosisHealth Affairs, 2013
- The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapyAnnals of Oncology, 2012
- The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancerGynecologic Oncology, 2009
- Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma.2002
- Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.Journal of Clinical Oncology, 1998